© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers.